Low dose of interferon-α improves the clinical outcomes of docetaxel in patients with castration-resistant prostate cancer: A pilot study

Low dose of interferon-α improves the clinical outcomes of docetaxel in patients with castration-resistant prostate cancer: A pilot study

The aim of this study was to test whether a low dose of interferon-α-2b (IFN-α2b) enhances the clinical outcome of docetaxel (DXT) in patients with castration-resistant prostate cancer (CRPC). A prospective controlled trial of 40 CRPC patients receiving 5 mg of prednisone twice daily was conducted,...

Full description

Bibliographic Details
Main Authors:	LI, YUN-FEI, WANG, QIN-ZHANG, ZHANG, TAO-TAO, LI, LEI, WANG, JIANG-PING, DING, GUO-FU, HE, DA-LIN
Format:	Online
Language:	English
Published:	D.A. Spandidos 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3861530/

Similar Items

Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
by: Wong, Hui-Li, et al.
Published: (2015)

The Influence of Prednisone on the Efficacy of Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer
by: Teply, Benjamin A., et al.
Published: (2015)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
by: Mahon, K L, et al.
Published: (2015)

Inhibition of Hsp90 Augments Docetaxel Therapy in Castrate Resistant Prostate Cancer
by: Ku, ShengYu, et al.
Published: (2014)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
by: Francini, Filippo, et al.
Published: (2011)

Synergistic Antitumor Activities of Docetaxel and Octreotide Associated with Apoptotic-Upregulation in Castration-Resistant Prostate Cancer
by: Zhu, Sha, et al.
Published: (2014)

Subverting ER-Stress towards Apoptosis by Nelfinavir and Curcumin Coexposure Augments Docetaxel Efficacy in Castration Resistant Prostate Cancer Cells
by: Mathur, Aditi, et al.
Published: (2014)

Docetaxel-Induced Fatal Interstitial Pneumonitis in a Patient with Castration-Resistant Prostate Cancer
by: Min, Byung-Dal, et al.
Published: (2012)

Prospective Evaluation of Low-Dose Ketoconazole Plus Hydrocortisone (HC) in Docetaxel Pre-treated Castration-Resistant Prostate Cancer (CRPC) Patients
by: Lo, Ernest N., et al.
Published: (2015)

Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space
by: Sartor, A Oliver
Published: (2011)

Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience
by: Nakano, Kazuhiko, et al.
Published: (2012)

Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis
by: Zhong, Lixian, et al.
Published: (2013)

Risk Factors for Metastatic Castration-Resistant Prostate Cancer (CRPC) Predict Long-Term Treatment with Docetaxel
by: Kawahara, Takashi, et al.
Published: (2012)

Predictive Factors for Premature Discontinuation of Docetaxel-Based Systemic Chemotherapy in Men With Castration-Resistant Prostate Cancer
by: Park, Seung Chol, et al.
Published: (2013)

External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer
by: Nakano, Kazuhiko, et al.
Published: (2014)

Metastatic castrate-resistant prostate cancer with a late, complete and durable response to docetaxel chemotherapy: a case report
by: Daverede, Luis, et al.
Published: (2014)

Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel
by: Araujo, John C, et al.
Published: (2013)

Gemcitabine–oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed
by: Lee, J-L, et al.
Published: (2014)

Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer
by: Lin, H-M, et al.
Published: (2014)

Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer
by: Kohli, Manish, et al.
Published: (2015)

Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America
by: Joshua, Anthony M., et al.
Published: (2015)

Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of Literature
by: Di Lorenzo, Giuseppe, et al.
Published: (2016)

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
by: Salvi, Samanta, et al.
Published: (2016)

Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer
by: Jang, Ho Seong, et al.
Published: (2016)

Enzalutamide (formerly MDV3100) prolongs survival in docetaxel-pretreated castration-resistant prostate cancer patients
by: Heck, Matthias M., et al.
Published: (2013)

Activity of enzalutamide in men with metastatic castration resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
by: Cheng, Heather H., et al.
Published: (2015)

Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy
by: Yamashita, Shimpei, et al.
Published: (2016)

Activation of AMPKα mediates additive effects of solamargine and metformin on suppressing MUC1 expression in castration-resistant prostate cancer cells
by: Xiang, SongTao, et al.
Published: (2016)

Nonmetastatic Castration-Resistant Prostate Cancer
by: Hong, Jun Hyuk, et al.
Published: (2014)

A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer
by: Qi, Ping, et al.
Published: (2015)

A Multicenter, Randomized Clinical Trial Comparing the Three-Weekly Docetaxel Regimen plus Prednisone versus Mitoxantone plus Prednisone for Chinese Patients with Metastatic Castration Refractory Prostate Cancer
by: Zhou, Tie, et al.
Published: (2015)

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel
by: Chi, K. N., et al.
Published: (2016)

MicroRNA-328 directly targets p21-activated protein kinase 6 inhibiting prostate cancer proliferation and enhancing docetaxel sensitivity
by: LIU, CHUNHUI, et al.
Published: (2015)

Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
by: Liu, Hsin-Ho, et al.
Published: (2014)

20(S)-Protopanaxadiol Inhibition of Progression and Growth of Castration-Resistant Prostate Cancer
by: Cao, Bo, et al.
Published: (2014)

Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)
by: Joseph M. Unger, et al.
Published: (2018-06-01)

GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells
by: Karanika, Styliani, et al.
Published: (2015)

Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison
by: Tan, Pui S, et al.
Published: (2014)

Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy
by: Okegawa, Takatsugu, et al.
Published: (2016)

Feasibility of classical secondary hormonal therapies prior to docetaxel therapy in Japanese patients with castration-resistant prostate cancer: Multicenter retrospective study
by: Kandori, Shuya, et al.
Published: (2016)